New hope for tough psoriasis spots: tildrakizumab under the microscope
NCT ID NCT05938361
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well tildrakizumab works for psoriasis in areas that are often hard to treat, like the scalp, nails, genitals, and palms. About 120 adults with moderate to severe psoriasis will receive tildrakizumab and be followed for up to 52 weeks. The goal is to see if the drug improves these stubborn spots and overall quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tildrakizumab (an injected antibody that blocks IL-23 to reduce inflammation)
What this could lead to
If successful, this could show that tildrakizumab is a good option for treating psoriasis in areas that are usually hard to manage, like the scalp, nails, genitals, and palms.
What could go wrong
This is a single-arm study with no placebo group, so results may be less reliable. It is also relatively small (120 people) and only follows participants for 52 weeks, so long-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS PALMARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Dermatologie- Hopital Saint Joseph
Paris, 75014, France